Spots Global Cancer Trial Database for metastatic breast cancer
Every month we try and update this database with for metastatic breast cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea | NCT05132101 | Metastatic Brea... | Patients who re... | 18 Years - | Pfizer | |
| SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer | NCT00270413 | Metastatic Brea... | SU11248 | 18 Years - | Universitaire Ziekenhuizen KU Leuven | |
| The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane. | NCT03619044 | HER2-positive B... | 2 FES-PET Imagi... | 18 Years - | Institut Claudius Regaud | |
| Docetaxel Combined With Ketoconazole in Treatment of Breast Cancer | NCT00212095 | Metastatic Brea... | docetaxel and k... | 18 Years - | National University Hospital, Singapore | |
| A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel | NCT01722968 | Breast Cancer | Bevacizumab Paclitaxel | 18 Years - 70 Years | Karolinska University Hospital | |
| Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons | NCT00627978 | Metastatic Brea... | ixabepilone | 18 Years - | Weill Medical College of Cornell University | |
| The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel | NCT01814150 | Metastatic Lung... Metastatic Brea... Metastatic Gast... Metastatic Pros... Metastatic Blad... | 18 Years - | Meir Medical Center | ||
| Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO) | NCT01160094 | Cancer | Treatment | 18 Years - | Novartis | |
| Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985 | NCT04983238 | Metastatic Brea... | BYON5667 & SYD9... Placebo & SYD98... | 18 Years - | Byondis B.V. | |
| Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer | NCT04703920 | Metastatic Brea... Metastatic Cast... Metastatic Ovar... | Talazoparib Belinostat | 18 Years - | University of Michigan Rogel Cancer Center | |
| Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer | NCT04857619 | Metastatic Brea... | None (Observati... | - | AstraZeneca | |
| Mammaglobin-A DNA Vaccine for Metastatic Breast Cancer | NCT00807781 | Metastatic Brea... | Mammaglobin-A D... | 18 Years - | Washington University School of Medicine | |
| HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer | NCT00401427 | Metastatic Brea... | trastuzumab vinorelbine | 18 Years - | National Cancer Institute, Naples | |
| Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects | NCT01516307 | Metastatic Brea... | OPT-822/OPT-821... Phosphate Buffe... Cyclophosphamid... | 21 Years - | OBI Pharma, Inc | |
| Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer | NCT01238029 | Metastatic Brea... HER2 Positive First or Second... Failure or Cont... | Lapatinib and C... | 18 Years - | Sponsor GmbH | |
| Therapy Management With Nab-Paclitaxel in Daily Routine | NCT02642406 | Metastatic Brea... | 18 Years - 99 Years | University Hospital Tuebingen | ||
| Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry) | NCT05964504 | Metastatic Brea... Lobular Breast ... | Blood Specimen | 18 Years - | University of California, San Francisco | |
| GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer | NCT01918306 | Estrogen Recept... Human Epidermal... Triple Negative... Recurrent Breas... Stage IV Breast... Triple-negative... | cisplatin laboratory biom... pharmacological... dynamic contras... GDC -0941 | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Efficacy of the Use of Refrigerant Helmet to Prevent Alopecia in Patients Treated With Eribulin for Breast Cancer | NCT02863146 | Breast Cancer Metastatic Brea... | 18 Years - | Centre Oscar Lambret | ||
| The Impact of Adverse Events, Produced by Antibodies Conjugates, on Quality of Life in Patients With Metastatic Breast Cancer: Multicentric, Observational Study (EVA). | NCT06106711 | Metastatic Brea... | 18 Years - | Centro di Riferimento Oncologico - Aviano | ||
| Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy | NCT05919212 | Metastatic Brea... | HER2-D is the u... | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer | NCT03892096 | Metastatic Non-... Metastatic Colo... Metastatic Brea... | Blood-based cel... | 18 Years - | Cadex Genomics | |
| Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer | NCT02129556 | Metastatic Brea... | MK-3475 | 18 Years - | ETOP IBCSG Partners Foundation | |
| DESTINY Breast Respond HER2-low Europe | NCT05945732 | Unresectable Br... Metastatic Brea... HER2-low Expres... | Trastuzumab der... | 18 Years - | Daiichi Sankyo | |
| Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC | NCT03184090 | Metastatic Brea... | Palbociclib Endocrine thera... | 18 Years - | MedSIR | |
| Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | NCT05191004 | Advanced Breast... Metastatic Brea... Breast Cancer Breast Carcinom... Cancer of the B... Cancer of Breas... Malignant Tumor... Breast Tumor | NUV-422 Fulvestrant | 18 Years - | Nuvation Bio Inc. | |
| Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer | NCT02470819 | Metastatic Brea... Breast Tumor Advanced Gyneco... | Genetic profili... | 18 Years - | Avera McKennan Hospital & University Health Center | |
| CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) | NCT02580448 | Cancer of the B... Breast Cancer Advanced Breast... Metastatic Brea... Male Breast Can... Triple Negative... ER+ Breast Canc... | Seviteronel | 18 Years - | Innocrin Pharmaceutical | |
| An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory | NCT01240421 | Metastatic Brea... | Eribulin Mesyla... | 18 Years - | Eisai Inc. | |
| Integrated Patient Avatars for Guiding Systemic Therapy Treatments in Metastatic Breast Cancer Patients | NCT04608357 | Breast Cancer Breast Neoplasm... Metastatic Brea... Cancer, Breast | Needle Core Bio... | 18 Years - | Sunnybrook Health Sciences Centre | |
| Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer | NCT01338831 | Castration-resi... Metastatic Brea... Uterine Leiomyo... | LFA102 | 18 Years - | Novartis | |
| HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer | NCT03685331 | Metastatic Brea... Locally Advance... Advanced Breast... BRCA2 Mutation BRCA1 Mutation | Palbociclib Olaparib Fulvestrant | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) | NCT01942135 | Metastatic Brea... | Palbociclib Fulvestrant Placebo Fulvestrant | 18 Years - | Pfizer | |
| Prospective Study of VEGFR-2 /IL-8 Genetic Interaction in MBC Treated With Paclitaxel and Bevacizumab vs. Chemotherapy | NCT02329639 | Metastatic Brea... | genetic interac... | 18 Years - | University of Pisa | |
| Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy | NCT02362230 | Metastatic Brea... | Icotinib | 18 Years - 65 Years | Sun Yat-sen University | |
| Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. | NCT05340413 | HER2-negative B... Metastatic Brea... Triple Negative... | Olaparib | 18 Years - | SOLTI Breast Cancer Research Group | |
| Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET | NCT04992156 | Metastatic Brea... | Palbociclib | 18 Years - 70 Years | Fudan University | |
| Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial | NCT06308939 | Metastatic Brea... | Eribulin Sintilimab | 18 Years - | Zhejiang Cancer Hospital | |
| Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial | NCT06308939 | Metastatic Brea... | Eribulin Sintilimab | 18 Years - | Zhejiang Cancer Hospital | |
| Fresolimumab and Radiotherapy in Metastatic Breast Cancer | NCT01401062 | Metastatic Brea... | Fresolimumab Radiation Thera... | 18 Years - | Weill Medical College of Cornell University | |
| Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer | NCT05176080 | Metastatic Brea... | Famitinib SHR6390 Fulvestrant | 18 Years - 75 Years | Henan Cancer Hospital | |
| A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer | NCT05584644 | Breast Cancer Breast Carcinom... Breast Neoplasm... Breast Tumors Cancer of Breas... | Palbociclib plu... Palbociclib plu... | 18 Years - 99 Years | Pfizer | |
| Trial of Ixabepilone in Patients With HER-2 Negative Metastatic Breast Cancer (HIT) | NCT00790894 | Metastatic Brea... | ixabepilone ixabepilone | 18 Years - 75 Years | Hellenic Cooperative Oncology Group | |
| Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors | NCT02028507 | Metastatic Brea... | Palbociclib Capecitabine Exemestane Fulvestrant | 18 Years - | Spanish Breast Cancer Research Group | |
| Phase II Dasatinib Study in Advanced Breast Cancer | NCT00546104 | Advanced Breast... | Dasatinib | 18 Years - | Duke University | |
| A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer | NCT00951665 | Metastatic Brea... | paclitaxel pertuzumab [Per... trastuzumab emt... paclitaxel trastuzumab emt... | 18 Years - | Genentech, Inc. | |
| Feasibility of Fasting & Exercise in Pts With HR+ MBC | NCT04708860 | Breast Cancer Metastatic Brea... | Prolonged Night... Exercise | 18 Years - | Dana-Farber Cancer Institute | |
| Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer | NCT02594371 | Metastatic Brea... | Oraxol IV paclitaxel | 18 Years - | Athenex, Inc. | |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | NCT04140526 | Non Small Cell ... Advanced Solid ... Metastatic Mela... Metastatic Head... Metastatic Rena... Metastatic Colo... Sarcomas Metastatic Pros... Ovarian Cancer Small Cell Lung... Metastatic Brea... Pancreas Cancer Gastric Cancer Esophageal Canc... Gastroesophagea... Cervical Cancer Adenoid Cystic ... Salivary Gland ... Urothelial Carc... | ONC-392 Pembrolizumab Docetaxel | 18 Years - | OncoC4, Inc. | |
| Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex | NCT00235937 | Breast Cancer | Anastrozole and... | 18 Years - | AstraZeneca | |
| Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC | NCT05131841 | Metastatic Brea... | Cipterbin Combi... | 18 Years - 70 Years | Zhejiang Cancer Hospital | |
| Nab-paclitaxel in Metastatic Breast Cancer Patients Failing Solvent Based Taxane (Tiffany) | NCT01416558 | Metastatic Brea... | Nab-Paclitaxel | 18 Years - | German Breast Group | |
| Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women | NCT01300351 | Breast Cancer | Fulvestrant Placebo | 18 Years - | AstraZeneca | |
| AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer. | NCT02102165 | Metastatic Brea... | metastatic lesi... | 18 Years - | Breast International Group | |
| First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer | NCT05216432 | PIK3CA Mutation Solid Tumor, Ad... HER2-negative B... Breast Cancer Metastatic Brea... Advanced Breast... Unresectable So... | RLY-2608 Fulvestrant Palbociclib 125... Ribociclib 400m... Ribociclib 600m... | 18 Years - | Relay Therapeutics, Inc. | |
| Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer | NCT00077025 | Breast Cancer | Gefitinib Anastrozole | 18 Years - | AstraZeneca | |
| A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer | NCT00251472 | Metastatic Brea... | Paclitaxel Albu... | 18 Years - | Veeda Oncology | |
| Mammaglobin-A DNA Vaccine for Metastatic Breast Cancer | NCT00807781 | Metastatic Brea... | Mammaglobin-A D... | 18 Years - | Washington University School of Medicine | |
| First Line Metastatic Breast Cancer Treatment (ESMERALDA) | NCT01941407 | Metastatic Brea... | Eribulin | 18 Years - | ARCAGY/ GINECO GROUP | |
| ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases | NCT00496379 | Breast Cancer CNS Disease | ZK219477 | 18 Years - | Dana-Farber Cancer Institute | |
| Discovering Factors in Metastatic Breast Cancer Patients' Clinical Trial Experiences | NCT05760183 | Metastatic Brea... | 18 Years - | Power Life Sciences Inc. | ||
| Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer | NCT03310957 | Triple Negative... | ladiratuzumab v... Pembrolizumab | 18 Years - | Seagen Inc. | |
| A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B) | NCT00434356 | Metastatic Brea... | bevacizumab sunitinib paclitaxel | 18 Years - | Genentech, Inc. | |
| Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers | NCT05765357 | Metastatic Brea... Metastatic Gast... | Trastuzumab for... Herceptin | 18 Years - 65 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy | NCT00109265 | Breast Cancer | Erlotinib HCl (... | 18 Years - | Genentech, Inc. | |
| The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC Patients | NCT02865304 | Angiogenesis Breast Cancer | endostar | 18 Years - 70 Years | Fujian Cancer Hospital | |
| Feasibility of Integrating the Outcomes4Me Smartphone Navigation Application Into the Care Management of Breast Cancer Patients | NCT04262518 | Breast Cancer Invasive Breast... Metastatic Brea... Breast Carcinom... Metastatic Brea... | Outcomes4Me Mob... | 18 Years - | Outcomes4Me | |
| Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer | NCT00952692 | Metastatic Brea... | dHER2 + AS15 AS... Lapatinib | 18 Years - | Duke University | |
| Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors | NCT04541225 | Glioma Glioma, Maligna... Glioma, Mixed Glial Cell Tumo... Breast Cancer Breast Carcinom... Cancer of Breas... Cancer of the B... Breast Tumor Malignant Tumor... Advanced Breast... Advanced Breast... Metastatic Brea... Metastatic Brea... Prostate Cancer Prostatic Cance... Cancer of Prost... Cancer of the P... Prostate Neopla... Castrate Resist... Castration-resi... Castration Resi... Glioblastoma Recurrent Gliob... | NUV-422 | 18 Years - | Nuvation Bio Inc. | |
| Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients | NCT04253561 | Metastatic Brea... | Ipatasertib Trastuzumab Pertuzumab | 18 Years - | SOLTI Breast Cancer Research Group | |
| TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) | NCT06125522 | Breast Cancer | vepdegestrant Samuraciclib | 18 Years - | Pfizer | |
| Halaven Patient Registry (Metastatic Breast Cancer, MBC) | NCT03245112 | Metastatic Brea... Advanced Breast... | Eribulin Mesyla... | 24 Years - 85 Years | Chang Gung Memorial Hospital | |
| Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant | NCT01019577 | Metastatic Brea... | Ixabepilone | 20 Years - | R-Pharm | |
| Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer | NCT00525096 | Metastatic Brea... | placebo Celecoxib Exemestane | 18 Years - | ARCAGY/ GINECO GROUP | |
| Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer | NCT03892096 | Metastatic Non-... Metastatic Colo... Metastatic Brea... | Blood-based cel... | 18 Years - | Cadex Genomics | |
| Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer | NCT00317720 | Breast Cancer Neoplasm Metast... | Trastuzumab RAD001 | 18 Years - | M.D. Anderson Cancer Center | |
| Vaccination With Flt3L, Radiation, and Poly-ICLC | NCT03789097 | Non-Hodgkin's L... Metastatic Brea... Head and Neck S... | Pembrolizumab Flt3L Radiation Poly ICLC | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1) | NCT00262067 | Metastatic Brea... | Bevacizumab Placebo Chemotherapy | 18 Years - | Genentech, Inc. | |
| Evaluate the Meritup Oral Solution to Decrease Fatigue in Metastatic Breast Cancer Patients Receiving Chemotherapy | NCT06151249 | Metastatic Brea... | Meritup oral so... | 20 Years - 80 Years | Chung Shan Medical University | |
| BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer | NCT00540800 | Breast Cancer | docetaxel epirubicin capecitabine | - 70 Years | National Cancer Institute, Naples |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
